University of Sussex
Browse
DOCUMENT
Figure 1-consort diagram.pdf (40.88 kB)
DOCUMENT
EXTREQOLrevised manuscriptclean version 15th Oct.pdf (556.49 kB)
1/0
2 files

Treatment experiences, information needs, pain and quality of life in men with metastatic castrate-resistant prostate cancer: results from the EXTREQOL study

journal contribution
posted on 2023-06-09, 15:49 authored by Valerie JenkinsValerie Jenkins, I Solis-Trapala, H Payne, M Mason, Lesley FallowfieldLesley Fallowfield, Shirley MayShirley May, L Matthews, Susan Catt
Aims Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment. Material and methods Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months. Results In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study. Conclusion Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted.

Funding

EXTREQoL - Experiences of treatment and Quality of Life of men with mCRPC; G1936; AVENTIS PHARMA LIMITED; E000108057

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Clinical Oncology

ISSN

0936-6555

Publisher

Elsevier

Issue

2

Volume

31

Page range

99-107

Department affiliated with

  • Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications

Research groups affiliated with

  • Sussex Health Outcomes Research and Education in Cancer Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2018-11-09

First Open Access (FOA) Date

2019-11-23

First Compliant Deposit (FCD) Date

2018-11-07

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC